EBF1 and cholangiocarcinoma: Decreased EBF1 expression resulting from genomic loss or somatic missense mutations were found in breast cancer (BC) (22, 23), pancreatic ductal adenocarcinoma (PDAC) (24), and cholangiocarcinoma (CCA) (25).